Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
PHASE3CompletedINTERVENTIONAL
Enrollment
421
Participants
Timeline
Start Date
June 5, 2014
Primary Completion Date
February 26, 2015
Study Completion Date
September 6, 2015
Conditions
Chronic Hepatitis C Virus
Interventions
DRUG
Grazoprevir 100mg / Elbasvir 50 mg FDC
DRUG
Placebo to Grazoprevir / Elbasvir 50 mg FDC
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02105467 - Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060) | Biotech Hunter | Biotech Hunter